ai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi's therapeutic development platform.

Company Website: https://www.glucotrack.com
RUTHERFORD, N.J., & LA JOLLA, Calif. -- (Business Wire)

Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The new structure reflects the growth of the Company's actual intelligence-driven platform and is designed to create opportunities for revenue generation while continuing to advance Lōkahi's core pharmaceutical development strategy.

Since its launch approximately one year ago, ai² has expanded from a single university collaboration to 13 participating universities and has identified and evaluated more than 45 therapeutic assets, with several programs advancing into active business diligence. The platform is intended to create a sustainable source of development opportunities for Lōkahi while also generating external interest from biotechnology companies, academic institutions, and strategic partners.

"One year ago, ai² was an idea. Today it has evolved into a capital-efficient platform capable of generating value on multiple fronts," said Erik Emerson, Chief Executive Officer of Glucotrack. "Importantly, this expansion does not change our commitment to developing late-stage therapeutic assets. Instead, it creates complementary business lines that can generate revenue, expand our network, strengthen deal flow, and support long-term shareholder value."

Three Complementary Growth Engines

ai² Pipeline™ is intended to serve as the Company's asset discovery and business development platform, identifying and evaluating overlooked, abandoned, and underdeveloped therapeutic opportunities. In addition to supporting Lōkahi's own pipeline, the division is expected to create partnership, licensing, and asset-originating opportunities for external organizations.

ai² Talent™ is designed to transform Lōkahi's growing university network into a biotechnology workforce development platform, connecting emerging talent with industry partners while providing specialized training across business, clinical, regulatory, intellectual property, manufacturing, and commercialization disciplines.

ai² Accelerator™ is expected to extend the ai² methodology beyond therapeutics by bringing together engineering, software, data science, and healthcare innovation teams to develop technology solutions addressing real-world challenges across biotechnology, diagnostics, patient monitoring, and digital health.

Together, these three divisions are intended to form a diversified growth platform that is expected to extend Lōkahi's pharmaceutical business through multiple potential revenue streams, including strategic partnerships, fee-for-service engagements, technology-driven data solutions, workforce development programs, and asset origination.

About Lōkahi Therapeutics™

Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai² program, please visit www.ai2equals.com.

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "anticipate," "believe," "expect," “intend,” “design,” "plan," and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to regaining and maintaining compliance with Nasdaq listing requirements; risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack's future distribution agreements; risks relating to its ability to hire and retain qualified personnel; risks related to Lōkahi, including the ability of Lōkahi’s ai² business divisions to generate revenue or achieve their anticipated benefits and the ability of Lōkahi to establish and maintain strategic partnerships, licensing arrangements, and collaborations; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908357637/en/

Contacts:

Glucotrack
GlucotrackPR@icrinc.com
Lōkahi Therapeutics™
ir@lokahithera.com

Source: Lōkahi Therapeutics Inc.